SMC Scottish Medicines Consortium
Advising on new medicines for Scotland
www.scottishmedicines.org.uk
NHS SCOTLAND
Delta House • 50 West Nile Street • Glasgow • G1 2NP • Tel 0141 225 6999 • Chairman: Dr Alan G MacDonald

Product Update

lacosamide, 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup and 10mg/mL solution for intravenous infusion (Vimpat®) SMC No 1301/18
UCB Pharma Ltd

12 January 2018

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

lacosamide (Vimpat®) is accepted for restricted use within NHS Scotland.

Indication under review: as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.

SMC restriction: patients with refractory epilepsy. Treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.

SMC has previously accepted lacosamide for restricted use as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 4 December 2017.

Chairman,
Scottish Medicines Consortium

Published 12 February 2018